title: Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi.
abstract: Minocycline-rifampin-impregnated central venous catheters (M/R CVCs) have been shown to be efficacious in reducing catheter-related bloodstream infections (CRBSI) and inhibiting the biofilm adherence of resistant Gram-positive and Gram-negative pathogens, with the exception of Pseudomonas aeruginosa and Candida spp. To expand the spectrum of antimicrobial activity, a novel second-generation M/R catheter was developed by adding chlorhexidine (CHX-M/R). CVCs and peripherally inserted central catheters (PICCs) were impregnated with CHX-M/R and compared with first-generation M/R catheters, CHX-silver sulfadiazine-treated CVCs (CHX/SS-CVCs), chlorhexidine-treated PICCs, and uncoated catheters. A biofilm catheter colonization model was used to assess the efficacy of catheters against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), P. aeruginosa, Candida albicans, and Candida glabrata. CHX-M/R-impregnated CVCs were the only antimicrobial catheters that completely inhibited the biofilm colonization of all resistant bacterial and fungal organisms tested at all time intervals, and they were significantly superior to uncoated catheters (all P values were ≤0.003). Furthermore, CHX-M/R-coated CVCs had a significantly more effective and prolonged (up to 3 weeks) antimicrobial activity against MRSA and P. aeruginosa than M/R, CHX/SS, and uncoated CVCs (P < 0.0001). Similarly, CHX-M/R-coated PICCs were also superior to M/R-coated and CHX-coated PICCs in preventing biofilms of MRSA, VRE, P. aeruginosa, and Candida species (P value = 0.003 for all). Our study shows that novel CHX-M/R-coated catheters have unique properties in completely inhibiting biofilm colonization of MRSA, VRE, P. aeruginosa, and fungi in a manner superior to that of M/R- and chlorhexidine-treated catheters.
authors: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. iraad@mdanderson.org
authors: Issam
authors: I
authors: Raad
authors: Jamal A
authors: JA
authors: Mohamed
authors: Ruth A
authors: RA
authors: Reitzel
authors: Ying
authors: Y
authors: Jiang
authors: Sammy
authors: S
authors: Raad
authors: Munirah
authors: M
authors: Al Shuaibi
authors: Anne-Marie
authors: AM
authors: Chaftari
authors: Ray Y
authors: RY
authors: Hachem
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000145:classification / Q000187:drug effects* / Q000254:growth & development; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D002175:Candida / Q000145:classification / Q000187:drug effects* / Q000254:growth & development; D002405:Catheterization, Central Venous; D002406:Catheterization, Peripheral; D002408:Catheters, Indwelling / Q000382:microbiology*; D002710:Chlorhexidine / Q000737:chemistry / Q000494:pharmacology*; D004352:Drug Resistance, Microbial / Q000187:drug effects; D004866:Equipment Contamination / Q000517:prevention & control; D006801:Humans; D008911:Minocycline / Q000737:chemistry / Q000494:pharmacology*; D012293:Rifampin / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D000890:Anti-Infective Agents; D008911:Minocycline; D002710:Chlorhexidine; D012293:Rifampin